T. . Sugiyama - Gynecology

Author Information

Toru Sugiyama is a prominent researcher and expert in the field of Gynecology, currently affiliated with the Department of Obstetrics and Gynecology at Iwate Medical University, Iwate, Japan. His extensive work focuses primarily on ovarian, fallopian tube, and peritoneal cancers, with a particular emphasis on innovative treatments and therapeutic strategies.

Research Contributions

Toru Sugiyama has made significant contributions to the field of gynecologic oncology through his research on various aspects of ovarian cancer, including the efficacy and safety of new treatments such as niraparib, bevacizumab, nivolumab, and epitope-peptide vaccinations. His work often involves clinical trials and the exploration of new therapeutic options for patients with advanced and resistant forms of cancer. His recent studies from 2020 and 2021 have focused on the genetic mutations associated with ovarian cancer in Japanese patients, as well as the potential of oncolytic viral therapies for HPV-related cervical cancer.

Aliases

Toru Sugiyama is also known by several aliases in academic publications, including T Sugiyama, T. . Sugiyama, and T. Sugiyama.

Publication and Citation Metrics

Metric	Value
Citation Count	6472
h-index	39
Paper Count	410

Publications:

O9-1 Updated results of a phase 2 study of niraparib in heavily pretreated high-grade serous ovarian cancer patients in Japan

DOI: 10.1016/J.ANNONC.2021.05.533

Year: 2021

Efficacy and safety of standard of care with/without bevacizumab for platinum‐resistant ovarian/fallopian tube/peritoneal cancer previously treated with bevacizumab: The Japanese Gynecologic Oncology Group study JGOG3023

DOI: 10.1111/cas.15185

Year: 2021

Nivolumab Versus Gemcitabine or Pegylated Liposomal Doxorubicin for Patients With Platinum-Resistant Ovarian Cancer: Open-Label, Randomized Trial in Japan (NINJA)

DOI: 10.1200/JCO.21.00334

Year: 2021

Frequency of homologous recombination associated gene mutations in Japanese patients with ovarian cancer

DOI: 10.1016/s0090-8258(21)00953-7

Year: 2021

14 Phase II trial evaluating efficacy and safety of standard of care with or without bevacizumab in platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer

DOI: 10.1136/ijgc-2020-igcs.14

Year: 2020

Phase 2 single-arm study on the efficacy and safety of niraparib in Japanese patients with heavily pretreated, homologous recombination-deficient ovarian cancer

DOI: 10.3802/jgo.2021.32.e16

Year: 2020

Anti-cancer immunotherapy using cancer-derived multiple epitope-peptides cocktail vaccination clinical studies in patients with refractory/persistent disease of uterine cervical cancer and ovarian cancer [phase 2]

DOI: 10.1080/2162402X.2020.1838189

Year: 2020

The post-progression survival of patients with recurrent or persistent ovarian clear cell carcinoma: results from a randomized phase III study in JGOG3017/GCIG

DOI: 10.3802/jgo.2020.31.e94

Year: 2020

The efficacy of a third-generation oncolytic herpes simplex viral therapy for an HPV-related uterine cervical cancer model

DOI: 10.1007/s10147-020-01823-6

Year: 2020

A phase 2 study of intraperitoneal carboplatin plus intravenous dose-dense paclitaxel in front-line treatment of suboptimal residual ovarian cancer

DOI: 10.1038/s41416-020-0734-9

Year: 2020

How Does Pregnancy Affect Back Pain?

How Does Efficacy Vary Among Different Treatments?

What are the Emotional and Psychological Effects?

Can Difficult Labor be Prevented?

What are the Alternatives to Artificial Insemination?

Can Epigenetic Changes Influence Fertility?

What Types of Gynecological Issues Can Be Addressed Through Video Conferencing?

What Role Does Conciseness Play in Medical Documentation?

What are Müllerian Duct Anomalies (MDAs)?

What Should You Do if You Are Pregnant or Planning Pregnancy?

Partnered Content Networks

Relevant Topics